Impact of <i>TP53</i> loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.

Theranostics · 2024 · PMC11373632 · PMID 39239510

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The p53 target genes FUCA1 , RAP2B and SESN1 showed a similar trend but did not reach statistical significance ( Supplementary Figure 3 ) 37 .

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Impact of &lt;i&gt;TP53&lt;/i&gt; loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.

The sentences

Impact of <i>TP53</i> loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.